Interim Analysis from the OPTIC Trial - A Dose-Ranging Study of 3 Starting Doses of Ponatinib

dc.creatorCortés, Jorge
dc.creatorLomaia, Elza
dc.creatorTurkina, Anna
dc.creatorMoiraghi, Beatriz
dc.creatorUndurraga Sutton, María Soledad
dc.creatorPavlovsky, Carolina
dc.creatorRojas, Christine
dc.creatorChuah, Charles
dc.creatorArthur, Christopher
dc.creatorApperley, Jane
dc.creatorKim, Dong-Wook
dc.creatorHochhaus, Andreas
dc.creatorRousselot, Philippe
dc.creatorRosti, Gianantonio
dc.creatorMauro, Michael
dc.creatorLipton, Jeffrey
dc.creatorNaranjo, Daniel
dc.creatorLiu, Guohui
dc.creatorSrivastava, Shouryadeep
dc.creatorDeininger, Michael
dc.date.accessioned2020-11-17T18:36:44Z
dc.date.available2020-11-17T18:36:44Z
dc.date.created2020-11-17T18:36:44Z
dc.date.issued2020
dc.identifierClinical Lymphoma Myeloma & Leukemia Volumen: 20 Páginas: S234-S234 Suplemento: 1 Abstract de reunión: CML-114 Sep 2020
dc.identifier2152-2650
dc.identifierhttps://repositorio.uchile.cl/handle/2250/177768
dc.languageen
dc.publisherCIG Media Group
dc.sourceClinical Lymphoma Myeloma & Leukemia
dc.subjectAcute lymphoblastic leukemia
dc.subjectChronic myeloid leukemia
dc.subjectCML
dc.subjectDose-ranging
dc.subjectOPTIC
dc.subjectPonatinib
dc.subjectTyrosine kinase inhibitor
dc.subjectT315I
dc.subjectTyrosine kinase inhibitor
dc.titleInterim Analysis from the OPTIC Trial - A Dose-Ranging Study of 3 Starting Doses of Ponatinib
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución